GRAIL: A Major Trial Disappointment
Source: SeekingAlpha
2026-02-21 08:18:11 ET
GRAIL, Inc. ( GRAL ) reported the extensive NHS-Galleri trial’s results alongside the company’s Q4 results. The trial results weren’t as good as was hoped; the stock has reacted very strongly due to the lack of statistically significant findings of clinical utility, being down by -50% following the study results as of writing. The trial came with major importance, in my opinion making a strong stock reaction justified....
Read the full article on Seeking Alpha
For further details see:
GRAIL: A Major Trial Disappointment
GRAIL Inc.
NASDAQ: GRAL
GRAL Trading
-4.34% G/L:
$42.28 Last:
892,349 Volume:
$43.44 Open:
GRAL Latest News
March 12, 2026 04:30:00 pm
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
March 11, 2026 07:20:00 am
Here's Why Grail Shares Crashed in February and Why it Could Be a Buying Opportunity
GRAL Stock Data
$4,041,676,881
35,687,321
0.29%
174
N/A
Medical Diagnostics & Screening
Healthcare
US
Menlo Park
